Partner With Us NRI

Astrazeneca Pharma India Ltd share Price Today

Company details

6M Return 36.71%
1Y Return 76.30%
Mkt Cap.(Cr) 16,098.25
Volume 4,088
Div Yield 0.37%
OI Chg %
Volume 4,088

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company AstraZeneca Pharma India announced FY24 results:

  • Revenue from Operations for FY24 stood at Rs 1,296 crore with substantial 29% increase.
  • Profit Before Tax is Rs 220 crore registering a commendable 64% growth (PBT before exceptional items at Rs 201 crore, up by 17% compared to previous financial year).
  • Earnings Per Share (EPS) for financial year stood at Rs 64.6 demonstrating a significant growth of 63%
  • The Board of Directors, at its meeting dated May 27, 2024, have recommended a final dividend of Rs. 24 per equity share for FY24, subject to approval of shareholders at the Annual General Meeting of the Company.

Sanjeev Panchal, Country President and Managing Director, AstraZeneca India, commented, " FY24 was one of the strongest years for us in the country and we take immense pride in our consistent performance. AstraZeneca India products sales for first  time cross Rs 1000 crore mark, delivering total revenue of almost Rs ~1300 crore with growth of 29% this year. A successful execution of our growth through innovation strategy is helping us propel our ambition to be pioneers in science and lead in specialist disease areasin India. Science is guiding us, and our remarkable pipeline progress with 9 new medicines and indication approvals that we received last year, positions us optimally and we feel motivated to bring more innovative therapies faster and closer to patients in India.

Our scientific progress and great support from different states, peers, and industry stakeholders positions us optimally to achieve our purpose of leaving no patients behind in the therapy areas we are present in and sustainably continue our strive to contribute to people, society, and the planet."

Bhavana Agrawal, Chief Finance Officer, added, "Our strong full year performance is reflection of company’s focus on being a specialist organization & strong operational execution. This achievement reflects our relentless pursuit of identifying and capitalizing on opportunities in a dynamic environment. It underscores our dedication to not only achieving financial excellence but doing so in a sustainable and strategic manner."

Result PDF

View Other Company Results

Astrazeneca Pharma India Ltd shares SWOT Analysis

Strengths (13)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Company with high TTM EPS Growth
  • Strong Annual EPS Growth

Weakness (0)

Data not found

Opportunity (2)

  • Negative to Positive growth in Sales and Profit with Strong Price momentum
  • RSI indicating price strength

Threats (1)

  • High PE (PE > 40)

Resistance and support

R1 6,532.1
R2 6,624.9
R3 6,700.9


S1 6,363.4
S2 6,287.4
S3 6,194.6
Delivery and volume
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-09-19 3152.55 74097 BSE
ISHARES MSCI INDIA SMALL-CAP ETF Block Purchase 2022-09-19 3152.55 6542 BSE
Name Category Shares
AstraZeneca Pharmaceuticals AB PROMOTER 75%


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Astrazeneca Pharma India Ltd Stocks COMPARISON

Financials( in Cr) Astrazeneca Pharma India Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 6,439.30 1,520.95 1,574.80 4,564.50 1,078.95
% Change -0.30 0.33 0.64 -0.53 -2.76
Mcap Cr 16,098.25 364,926.86 127,144.16 121,173.33 108,567.62
Revenue TTM Cr 1,002.97 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 99.29 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 107.99 36.34 29.68 76.10 28.94
1 Year Return 76.30 54.15 60.91 30.94 102.68
ROCE 30.47 16.79 14.76 19.30 16.25
ROE 22.95 16.46 10.66 14.89 14.05

Equity Capital: 588.69 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 32,452.94 -2,589.17
LAST 3M 105,794.56 -32,067.62
LAST 6M 178,880.68 -18,917.36
LAST 12M 290,144.87 98,834.05
AstraZeneca Pharma India Limited - Loss of Share Certificates

Jun 14, 2024 l NSE Announcement

AstraZeneca Pharma India Limited - Trading Window

Jun 13, 2024 l NSE Announcement

Date Action Type Ratio
Jul 14, 2023 Dividend 800
Jul 07, 2022 Dividend 400

Astrazeneca Pharma India Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • AstraZeneca Pharmaceuticals Ltd is in the Pharmaceuticals sector is having a market capitalization worth Rs. 7,640.88 crores, it is incorporated in the year 1979. It has reported standalone sales of Rs. 175.40 crores in June 2021. The company is listed on the Bombay Stock Exchange (BSE) with the code 506820, and also listed on the National Stock Exchange (NSE) with the code ASTRAZEN.

    AstraZeneca Pharma deals in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology, and respiratory. It has a workforce of 1400 people across the country. Its manufacturing facility is certified with ISO 14001. AstraZeneca has established a Research & Development facility in Bangalore equipped with a team of 90 employees consisting of scientific experts in the field of regulatory science, clinical science, and patient safety. Its production unit is located in the city of Bengaluru. The company’s plant was the first pharma facility in India to be accredited with Gold Standard Rating under LEED (Leadership in Energy and Environmental Design) certification. The promoters own 75.0% of the stake in the company, Foreign Institutional Investors (FII) own 2.42% of the stake, Domestic Institutional Investors (DII) own 1.02%, and others (such as public & retail investors) hold the balance of 21.56%.

    In June 2021, quarterly net revenue was Rs. 175.4 crores, which has decreased by approximately 9.39 % from Rs. 193.58 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 10.24 crores, which has improved sharply and decreased by nearly 45.03% from a net profit of Rs. 18.63 crores in June 2020. In June 2021, the reported operating profit was at Rs. 141.09 crores, which is decreased by 11.79% as compared to an operating profit of Rs. 159.95 crores for the quarter ending in June 2020. From an EPS of Rs. 18.63 in June 2020, the EPS of AstraZeneca Pharmaceuticals Ltd has reduced and reached an EPS of Rs. 10.24 per share in June 2021. ASTRAZEN's stock closed at Rs. 3,056.35 on 27th August’2021 (NSE). AstraZeneca Pharmaceuticals Ltd has returned 11.06% negatively in the last six months and returned 13.50% negatively in the previous year.

Registered Address

Blk N1 12th Flr Manyata Embass, Rachenahalli Outer Ring Road, Bangalore, Karnataka, 560045

Tel : 91-080-67748000
Email : comp.secy:astrazeneca.com
Website : http://www.astrazeneca.in

Alpha Systems Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 506820
Book Closure Date (Month) :
BSE Group : A
ISIN : INE203A01020

FAQ’s on Astrazeneca Pharma India Ltd Shares

You can buy Astrazeneca Pharma India Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Astrazeneca Pharma India Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 18, 2024 03:49 PM the closing price of Astrazeneca Pharma India Ltd was Rs.6,439.30.

The latest PE ratio of Astrazeneca Pharma India Ltd as of Jun 18, 2024 03:49 PM is 107.99

The latest PB ratio of Astrazeneca Pharma India Ltd as of Jun 18, 2024 03:49 PM is 0.04

The 52-week high of Astrazeneca Pharma India Ltd share price is Rs. 7,220.95 while the 52-week low is Rs. 3,575.00

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 18, 2024 03:49 PM, the market cap of Astrazeneca Pharma India Ltd stood at Rs. 16,098.25.

Download App

Download Our App

Play Store App Store
market app